Somnomed Ltd
ASX:SOM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Somnomed Ltd
Cash & Cash Equivalents
Somnomed Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Somnomed Ltd
ASX:SOM
|
Cash & Cash Equivalents
AU$18m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
9%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Cash & Cash Equivalents
AU$6.6m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
29%
|
CAGR 10-Years
0%
|
|
|
Cochlear Ltd
ASX:COH
|
Cash & Cash Equivalents
AU$187.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
9%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cash & Cash Equivalents
AU$17.7m
|
CAGR 3-Years
79%
|
CAGR 5-Years
14%
|
CAGR 10-Years
34%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Cash & Cash Equivalents
AU$15.2m
|
CAGR 3-Years
30%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cash & Cash Equivalents
AU$17.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Somnomed Ltd
Glance View
SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.
See Also
What is Somnomed Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
18m
AUD
Based on the financial report for Dec 31, 2025, Somnomed Ltd's Cash & Cash Equivalents amounts to 18m AUD.
What is Somnomed Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
9%
Over the last year, the Cash & Cash Equivalents growth was -3%. The average annual Cash & Cash Equivalents growth rates for Somnomed Ltd have been 2% over the past three years , -6% over the past five years , and 9% over the past ten years .
